Key Highlights

  • The net loss deepened to USD 40.1 million, or USD 1.08 a share, from USD 10.0 million, or USD 0.29, largely because of a USD 31.3 million non-cash derivative charge.
  • Sales slipped 19% to USD 25.3 million, as CDMO Revenue fell 18% to USD 17.8 million and hyaluronic acid Manufacturing dropped 19% to USD 7.5 million.
  • Gross Margin rose to 27.0% from 25.0%, and operating spending fell 29% to USD 7.7 million, which shrank the operating loss to USD 0.9 million.
  • Under a signed deal dated September 27, 2026, Webster Equity Partners affiliates would pay USD 6.28 a share in cash plus a contingent value right, with completion anticipated by year-end 2026.

A Non-Cash Derivative Charge Widens the Net Loss

Lifecore Biomedical (NASDAQ:LFCR) submitted its third-quarter 10-Q on November 4, 2026. The company works as a contract development and manufacturing organization for sterile injectables and produces non-animal hyaluronic acid. Despite a net loss of USD 40.1 million, the operating loss was only USD 0.9 million, versus USD 3.1 million a year before. The difference stems from a USD 31.3 million rise in the Fair Value of a related-party Debt derivative, which the filing connects to the Merger agreement, since that agreement raised the likelihood and moved up the timing of a change in control. The Liability stood at USD 62.2 million, including an assumed change in control payment of about USD 30.0 million.

Price Concessions and Timing Weigh on Revenue

Revenue fell USD 5.8 million. CDMO revenue dropped USD 4.0 million: lower Volume cost USD 3.7 million and lower pricing cost USD 2.3 million, the latter tied to a concession granted to a customer for a multi-year commercial agreement extension, which outweighed USD 1.7 million of higher development income. Hyaluronic acid revenue decreased USD 1.8 million, reflecting the timing of the largest customer's Supply chain initiatives. Gross Profit slipped to USD 6.8 million despite the better margin. Selling, general and administrative expenses dropped USD 2.6 million to USD 6.3 million, helped by lower Stock Compensation and accounting fees, although merger-related spending in the current period partly offset that. Interest expense, net rose 24% to USD 7.9 million as interest on the Alcon term Loan accrues.

Merger Consideration, Closing Hurdles and the Stockholders' Deficit

Each common share would be exchanged for USD 6.28 in cash plus one contingent value right that pays milestone amounts when and if they become payable, while Series A preferred holders would get a defined conversion amount plus a right of their own. Completion requires stockholder approval and regulatory clearances, and the common stock would be removed from Nasdaq afterward. Cash stood at USD 23.0 million on September 30, 2026, up from USD 17.5 million at December 31, 2025, while the stockholders' Deficit reached USD 73.4 million. The filing lists risks tied to covenants, preferred stock redemptions and additional financing if the transaction collapses.

Where Things Stand

Mainly the merger, not weaker operations. Lifecore Biomedical (NASDAQ:LFCR) posted an operating loss of USD 0.9 million, narrower than last year, but a USD 31.3 million non-cash derivative charge widened the net loss to USD 40.1 million. Sales fell 19% on volume, a price concession and customer timing. Next markers include the stockholder vote, regulatory approvals, the expected close at year-end 2026 and the contingent value right terms. The filing gives no price reaction, guidance or milestone amounts.